戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              MAOI treatment decreased the magnitude of both 8-OH-DPAT
2                                              MAOI treatment induces TAM reprogramming and suppresses
3 y reduced potential for myelosuppression and MAOI.
4 ce, we report contrasting effects of chronic MAOI (phenelzine) and TCA (imipramine) treatment on neur
5                                    Combining MAOI and anti-PD-1 treatments results in synergistic tum
6 rmalize HPA function in atypical depression, MAOI would differ from TCA in decreasing rather than inc
7 oing classical monoamine oxidase inhibiting (MAOI) drug therapy.
8 uppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse ef
9 mg/kg), and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg) increased BDNF protein level
10 ically with the monoamine oxidase inhibitor (MAOI), clorgyline, and then injected with 8-OH-DPAT or v
11        Because monoamine oxidase inhibitors (MAOI) are often more effective than tricyclic antidepres
12 in the brain; small molecule MAO inhibitors (MAOIs) are clinically used for treating neurological dis
13 n and therapeutic benefit of MAO inhibitors (MAOIs) for cancer treatment, highlighting the roles of M
14                Monoamine oxidase inhibitors (MAOIs) exert therapeutic actions by elevating extracellu
15 ously assessed monoamine oxidase inhibitors (MAOIs) for their ability to inhibit the reaction catalyz
16  activity with monoamine oxidase inhibitors (MAOIs) results in the accumulation of repressive chromat
17 tidepressants, monoamine oxidase inhibitors (MAOIs), fluoxetine, or placebo were examined in a retros
18 ants [AA], and monoamine oxidase inhibitors [MAOI]), age, sex, smoking, mild systemic diseases, and i
19                                 Irreversible MAOIs cause serious hypertensive crises owing to periphe
20 herefore, we concluded that pretreatments of MAOI pharmacologically alter the activity of postsynapti
21 e role of tyramine in the central effects of MAOIs remains elusive, an issue addressed herein.
22 ranscriptional, and neurochemical effects of MAOIs.
23 ion between inhibitors of monoamine oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-H
24 al regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunother
25                                  Strikingly, MAOIs also block the reactivation of HSV from latency in
26 ed in rats by once daily pretreatment of the MAOI clorgyline for 3, 6, or 13 days.
27 men had a statistically superior response to MAOIs, this difference may not be clinically relevant.
28 men had a statistically superior response to MAOIs.
29 ed measures of glutamate were conducted with MAOIs in wild-type and TAAR1-knockout (KO) mice.